US Patent
US8993600 — Modulators of ATP-binding cassette transporters
Formulation · Assigned to Vertex Pharmaceuticals Inc · Expires 2030-12-11 · 5y remaining
Vulnerability score
39/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects compounds that modulate ATP-Binding Cassette transporters, including those used to treat diseases such as cystic fibrosis.
USPTO Abstract
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (âABCâ) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (âCFTRâ). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.